Guide · Published 29 October 2026 · Last reviewed 29 October 2026

Tapering off Mounjaro or Wegovy: does coming off slowly stop the weight coming back?

Written by Jaz Sandhu, Health and Wellbeing Coach and founder of Perdura

If you're thinking about tapering off Mounjaro or Wegovy, you've probably already read the headlines: most people who stop a GLP-1 medication regain a large share of the weight within a year. Tapering — stepping down your dose gradually instead of stopping outright — is increasingly suggested as the answer.

It can help. But a taper doesn't keep weight off by itself. What keeps weight off is what you build while the dose is coming down. This guide covers what tapering is, what the evidence actually shows, and how to use the step-down period so you're not relying on the medication when it's gone.

At Perdura, this step-down window is the part of GLP-1 weight management we focus on, because it's where most of the long-term result is won or lost.

What tapering actually means

Tapering is a planned reduction in dose over a period of weeks or months, rather than taking your last full-strength injection and stopping. For tirzepatide (Mounjaro) and semaglutide (Wegovy, Ozempic), that usually means stepping back down through the lower doses you went through when you started.

Some people never go all the way to zero. Instead they stay on the lowest dose that keeps their weight stable, which is often called a maintenance dose.

There is no official tapering schedule for either medication. How fast you step down, how long you stay at each dose and whether you stop completely are clinical decisions for your prescriber. This guide doesn't give doses and you shouldn't take them from any article online.

Why the “stopping” research looks so bad

Most of the frightening numbers come from clinical trials where people stopped suddenly:

• STEP 1 extension (semaglutide) — people who stopped after 68 weeks regained around two-thirds of the weight they had lost within a year.
• SURMOUNT-4 (tirzepatide) — after 36 weeks on Mounjaro, people switched to a placebo regained a substantial part of their loss over the following year, while those who stayed on kept losing.
• BMJ meta-analysis, January 2026 — across 37 studies, weight came back at roughly 0.8 kg a month after stopping semaglutide or tirzepatide, which puts people on track to return to their starting weight in about a year and a half. People coming off diet-and-exercise programmes regained far more slowly.

Two details are worth knowing.

First, in almost every trial the medication was stopped abruptly, with no step-down and usually no structured support. That's a clean experiment, not a realistic plan.

Second, the picture isn't all regain. A University of Cambridge review published in March 2026 modelled what happens after the first year and projected that regain levels off, leaving roughly a quarter of the lost weight still off — though that plateau is an extrapolation beyond the trial data, and the measured figure at one year was around 60 per cent regained. A large real-world study from Cleveland Clinic, also published in 2026, found regain after stopping was far less severe than the trials suggested; notably, around a fifth of those patients restarted their original medication and about a quarter switched to another, which the authors suggest is part of the explanation.

So regain is common, but it isn't fixed. How you stop, and what you have in place when you do, makes a difference.

What the evidence says about tapering

There are two honest points to make here.

The evidence is still early. As of late 2026, there is no large randomised trial directly comparing a gradual taper with stopping outright. Most of the supportive data is observational, or comes from providers reporting on their own patients. It's encouraging, but it isn't settled.

The logic is sound. On full-strength medication, appetite and food noise are heavily suppressed. Stopping suddenly removes that suppression over a few weeks, so hunger, cravings and the constant mental chatter about food can all return at once. A taper lets appetite come back gradually. That gives you time to notice what changes, adjust, and practise your habits while you still have some support.

That last part is the real value of a taper: it's a practice window.

Why a taper on its own isn't enough

A taper slows down how fast the medication's support disappears. It doesn't replace that support with anything.

If nothing changes about how you eat, move, sleep and manage stress during the taper, you've just made the regain slower. The people who do best treat the step-down as the most important phase of treatment, not the end of it.

The common mistake is waiting until you feel hungry again before putting habits in place. By then you're building new routines at the same moment your appetite is at its loudest. The best time to build them is while the medication is still doing some of the work.

What to build while you step down

1. An eating structure that holds when appetite returns

On medication, many people eat very little and quite randomly, because they simply aren't hungry. That pattern won't hold once appetite returns. Before and during your taper:

• Eat regular meals at roughly consistent times. Long gaps followed by a large evening meal are where regain often starts.
• Build every meal around protein. Protein is the most filling macronutrient and it helps protect muscle. A palm-sized portion or more at each meal is a reasonable starting point.
• Add fibre and volume. Vegetables, beans, lentils and whole grains add fullness without many calories.
• Plan for food noise. Expect the mental chatter about food to return. Knowing it's a biological signal, not a lack of willpower, makes it far easier to manage. Our guide to food noise explains why it comes back.

2. Resistance training

Rapid weight loss on GLP-1 medication can include a meaningful amount of muscle. Muscle supports your metabolic rate, blood sugar control and strength, and it matters even more for women in midlife, when falling oestrogen already speeds up muscle loss. Two or three sessions of resistance training a week, done consistently, is one of the strongest protections against regain.

3. Sleep and stress

Short sleep raises hunger hormones and makes high-calorie foods more appealing. Chronic stress does the same. Neither is a side issue. If your sleep is poor or your stress is high, fixing that before you step down will make the taper noticeably easier.

4. Track the right things

The scale on its own is a blunt tool. During a taper, track:

• Your weekly average weight, not daily readings, which naturally fluctuate by a kilo or more.
• Your waist measurement every two weeks.
• Your hunger and food noise, rated 1 to 10 each day. This often shifts before your weight does, so it's your early warning.

5. Decide your line in advance

Agree a threshold with yourself and your prescriber before you start — for example, a set amount of regain over a set number of weeks. Decide what happens if you cross it: tighten the plan, slow the taper or go back up a dose. Making that decision calmly in advance is much easier than making it in the middle of a difficult month.

Questions to ask your prescriber before you taper

• Do you recommend tapering, or stopping, in my situation, and why?
• What would a step-down look like for me, and how long would it take?
• Is a long-term maintenance dose an option for me?
• What should I monitor during the taper, and when should I contact you?
• If I regain weight, can I go back up a dose, and at what point would you suggest it?
• Will stopping affect any other medication or condition I have?

For a fuller list, see our complete guide to coming off weight loss injections.

Taper, stop or stay on?

Staying on a GLP-1 medication long term is a legitimate choice. For some people, that's the right clinical answer. But many people stop because of cost, side effects, a time limit on their prescription, or simply because they want to. Whichever route you take, the habits are the same and they're never wasted.

If you're stopping, our guides on what happens when you stop Mounjaro and coming off Wegovy cover what to expect week by week.

Frequently asked questions

Should I taper off Mounjaro or stop all at once?

That's a decision for your prescriber, based on your health and history. Many clinicians now prefer a gradual step-down because it lets appetite return more slowly, but there is no official tapering protocol for Mounjaro or Wegovy and the evidence comparing the two approaches is still limited.

How long does it take to taper off Wegovy or Mounjaro?

There's no fixed timeline. Step-downs are usually planned over weeks to months, depending on your current dose, how your appetite responds and how your weight tracks. Your prescriber will set the pace.

Will I still regain weight if I taper?

You may regain some weight. A taper reduces the shock of stopping, but the habits you build during it largely decide how much you keep off. In trials where people stopped suddenly with no support, regain was highest.

What is a maintenance dose?

A maintenance dose is the lowest dose that keeps your weight stable. Some people stay on it long term instead of stopping completely. Whether it's suitable for you is a conversation for your prescriber.

When does appetite come back after stopping a GLP-1?

Tirzepatide and semaglutide both take several weeks to clear the body. Many people notice their appetite and food noise returning within two to four weeks of their last dose, which is why it helps to have your eating structure in place before then.

How can Perdura help when I'm coming off a GLP-1?

Perdura is a UK coaching programme for people coming off GLP-1 weight loss medication. The Perdura Off-Ramp Programme gives you 16 weeks of one-to-one coaching on nutrition, resistance training, sleep, stress, food noise and habits, so your weight stays stable as the medication's effect wears off. Perdura doesn't prescribe or advise on medication; your prescriber stays in charge of that.

Sources

1. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022.
2. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA, 2024.
3. West S et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ, January 2026.
4. University of Cambridge. Systematic review and meta-regression of weight regain after stopping GLP-1 receptor agonists. eClinicalMedicine, March 2026.
5. Cleveland Clinic. Real-world weight outcomes after discontinuing semaglutide or tirzepatide. Diabetes, Obesity and Metabolism, March 2026.